Lutetium 177 PSMA Therapy in India

Lu PSMA Therapy

Lutetium Prostate-Specific Membrane Antigen (Lu-PSMA) therapy is a treatment for patients with advanced-stage prostate cancer or those who have become refractory to standard treatment approaches. The therapy is a high precision treatment that can help prevent damage to healthy surrounding tissue while delivering high dose radiation to the tumour cells.

The therapy aims to:

  • Stop multiplication of tumour cells or slow their growth.
  • Reduce tumour size.
  • Provide relief from symptoms such as pain caused by cancer and improve the quality of life of the patients.

How does it work?

  • Prostate-Specific Membrane Antigen (PSMA) is a unique receptor present on the surface of cells of the prostate gland. 
  • PSMA is overexpressed in prostate cancer cells and increases with tumour progression. 
  • If cancer spreads to the other parts (metastasizes), the PSMA receptor also appears on the sites where cancer has metastasized. 
  • Therefore, this receptor is an excellent target for nuclear imaging as well as treatment for prostate cancer.
  • The radionuclide therapy uses a molecule that can attach to the PSMA receptors present on the cancer cells in the body
  • Lutetium-177 is a radioactive element that emits low-energy beta radiations that can damage or kill the cancer cells when in close proximity. 
  • In Lu PSMA therapy, the radioactive substance is bound to a small protein molecule that can attach to the PSMA receptor on prostate cancer cells. 
  • This Lu-177 – PSMA complex targets the prostate cancer cell specifically and emits radiation to destroy these cells. 
  • As the penetration of the emitted beta radiation is low, it does not affect the healthy normal cells near the tumour.

Get a Free Personalized quote for Lu-PSMA Therapy in India

(jpeg, jpg, doc, docx, pdf)

Who are the suitable candidates for Lu PSMA?

Currently, the therapy is being offered to patients with advanced castration-resistant prostate cancer that is metastatic and has evidence of cancer progression.

Tumour progression can be determined by:

  • High serum PSA levels
  • Increase in the tumour size or number of the metastatic lesions as seen by CT/MRI scan or Ga68 PSMA scans
  • Worsening of pain or other symptoms


  • High-grade renal insufficiency
  • Bone marrow depletion
  • Acute haematological problems

Lu PSMA therapy is not contraindicated to patients having subsequent chemotherapy or radiation therapy if needed.


  • The patient is admitted to the hospital for 24 hours and has to stay in a Specialised High Dose Radioisotope Therapy Unit for radiation protection.
  • Lu177-PSMA compound is administered intravenously as an infusion.
  • MAG3/EC scan, a kidney function test, is done before Lu177 PSMA is administered.
  • Usually, patients are hydrated with intravenous fluids and an amino acid solution before and after Lu177 PSMA administration. This is to protect the renal functions.
  • Most patients need 3-4 treatment cycles with an interval of 8-12 weeks. 
  • The number of cycles, as well as interval duration, varies on the basis of the patient’s response to the treatment and medical assessment.
  • The average dose of the Lu 177 PMSA is in the range of 5.5 – 11GBq per treatment cycle. 
  • Required doses for every patient is determined on the basis of pre-treatment dosimetry (calculation of the ionising radiation dose absorbed by the human body).


  • Lu PSMA Therapy is a highly specific and precise therapeutic technique that has been showing great potential for the management of metastatic prostate cancer especially when other types of treatment methods fail to show improvement.
  • After Lu177 PSMA therapy, Over 70% of patients have experienced a reduction in Prostate-Specific Antigen (PSA) level and a reduction in tumour size. 
  • Almost all the patients had a reduction in pain and an overall improvement of health following the second dose of therapy.

Side effects

  • Lu PSMA is typically well tolerated by patients and does not have any significant adverse effects following the injection.
  • Some common side effects include a slightly dry mouth, tiredness and nausea. 
  • There may be a small drop in the number of white blood cells and platelets around 2 – 3 weeks after the Lu177 PSMA therapy. 
  • The side effects are usually mild and temporary. 
  • Patients recover soon without any treatment and the risk of serious or life-threatening complications is very low.

Happy Lyfboat Patients

Send via Email

Six Simple Steps

Free Access to the Network

Our medical advisory platform automatically sends your medical query to our network of expert Doctors, working only at top internationally accredited Hospitals.

Direct Communication

You and the medical providers communicate directly via email or your online patient account; our case managers are always available to help you with this.

Get Verified Quotations

You receive medical opinions and cost estimates within 24 to 48 hours via email and your online patient account.

Compare Quotes & Advices

Lyfboat empowers you to compare the medical opinions, and discuss the options with our very own doctors who help answer your questions, and guide you in making informed decisions on the best treatment option.

Get Discounted Costs

We negotiate your final costs, explore available discount offers, and we handle all your logistics including travel, accommodation, transport, and medical co-ordination.

Return Home Fit

Get cured, pay hospital after treatment and return home safe. Our care team is available throughout your journey to good health!

Dr. Joya Dubey

Written By Dr. Joya Dubey

Dr. Joya Dubey, a proficient healthcare professional, serves as a dedicated member of the organization, committed to assisting patients worldwide with empathy. Armed with a medical degree, coupled with a master's in healthcare management, Dr. Dubey takes the lead in pioneering efforts to transform healthcare delivery, with a primary focus on enhancing patient welfare and organizational advancement.
Free Enquiry